Barr Receives Tentative Approval For Generic KYTRIL(R) Tablets, 1mg (Base) (Medical News Today)
Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, Barr Laboratories, Inc. has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of Roche Laboratories Inc.'s KYTRIL(R) (granisetron hydrochloride) Tablets, 1mg (base). [click link for full article]

Orchid Chemicals standalone net slides marginally to Rs 28.32 Cr in Q3 (PharmaBiz)
Orchid Chemicals and Pharmaceuticals, a Rs 950-crore plus Chennai based pharma major, suffered minor setback during the third quarter ended December 2006 and its standalone net profit declined to Rs 28.32 crore from Rs 28.96 crore in the corresponding period of last year, mainly due to stagnant growth in top line.

Barr Will Host an Earnings Conference Call on February 28, 2007 to Discuss the Results for the Quarter and Six Months ... (PR Newswire via Yahoo! Finance)
Barr Pharmaceuticals, Inc. today announced that the Company will host a Conference Call at 8:30 AM Eastern time on Wednesday, February 28th to discuss earnings results for the quarter and six month period ended December 31, 2006.